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Adoptive transfer of autologous T cells genetically engi-
neered to express chimeric antigen receptors (CARs)
has emerged as a promising approach for the treatment
of cancer. To this end, we have been developing an
anti-BMCA CAR T cell approach for the potential treat-
ment of multiple myeloma. B cell maturation antigen
(BCMA) is an attractive CAR T cell target since nearly
all multiple myeloma tumor cells express BCMA, while
normal tissue expression is restricted to plasma cells
and a subset of mature B cells. However, to fully realize
the therapeutic potential of these engineered T cells will
require the development of simple and robust manufac-
turing processes capable of supporting larger clinical
studies as well as the scale up to commercial cell pro-
duct generation.
Bluebird bio’s approach has focused on developing a
simple and robust closed system manufacturing process
that could be readily transferrable to cGMP manufactur-
ing. Briefly, cultures are initiated with autologous PBMC
in the presence of anti-CD3 and anti-CD28 antibodies
obviating the need for T cell selection. Activated T cells
are then efficiently transduced with an anti-BCMA Lenti-
viral vector by direct inoculation of the culture with the
virus. The T cells are then expanded for a relatively short
period of 7-10 days in gas permeable culture bags. Finally,
cells are harvested, washed and cryopreserved in the final
formulation for infusion.
Using the above clinical manufacturing platform, we
consistently achieve greater than 6 population doublings
in 7-10 days, starting with as little as 100e6 PBMC.
Despite using PBMC as input, the purity of the cell pro-
duct after expansion is >99 % CD3+. Moreover, by using
our experience in generating clinic ready high titer Len-
tiviral vectors we are able to consistently achieve >50 %
of the T cells expressing the anti-BCMA CAR from a
single round of transduction with an average vector
copy number of 1.73 ± 0.43 Importantly, the anti-
BCMA CAR T cells manufactured using the above plat-
form retain potent anti-tumor activity both in vitro and
in vivo.
In summary, the Lentiviral-based CAR T cell manu-
facturing platform we have established is robust, and
results in a high quality cell product. Importantly, this is
achieved with fewer complex manipulations representing
an important step toward the development of CAR
T cell products.
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